PMDS is on track to reach positive cash flow by the year-end 2024, and the company will repeat its t...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) meddelade den 21 augusti år 202...
Redeye comments on Northbaze Q2 2024 report. The Q2 2024 report was better than expected with sales ...
Redeye’s first comments on the Q2 report this morning.
Redeye views Acarix's Q2 as weaker than anticipated, with lower-than-expected revenues.
Solteq had released preliminary Q2 figures ahead of the earnings report and the comparable net sales...
Redeye provides its initial take on Surgical Science’s Q2 2024 report, which featured a notable sequ...
Redeye stated that Gapwaves’ Q2 2024 report exceeded its, and consensus expectations.
Redeye sees a mixed Q2 report from BrightBid, with slow q/q cARR growth as the weak spot and solid c...
Redeye updates its view on Genovis following the Q2 report and the announced divestment of its antib...
Redeye states that while the Q2 report was soft, it had some positive highlights - including the seq...
Redeye saw a Q2 report in which sales and gross margins did not deviate much from our expectations, ...
Redeye remains cautious about Payday 3's comeback. While increased player activity following new con...
Redeye updates its view on Flexion Mobile following its Q2 2024 report.
Rec. PTP beat on NOI-margins and hedging Expect call of hybrid bonds in September Report leads us to...
Zoomability Int AB (”Zoomability” eller ”bolaget”) publicerade den 21 augusti 2024 bolagets delårsra...
Omsättningen minskade under kvartalet och höga nedskrivningar pressar rörelseresultatet.
Q2 in line: sales up 11% y-o-y, adj. EBIT margin 37% (24%) Guides for -0.
Redeye gives an initial take on the positive phase IIa results in RVO with ANXV, an imporant milesto...
Redeye is encouraged to see AroCell recording its first quarter with a positive cash flow, and the r...
